HLIB Research

PP 9484/12/2012 (031413)

ViTrox Corp (BUY ←→, EPS ←→)

INDUSTRY: OVERWEIGHT EARNINGS EVALUATION

22 August 2014 Price Target: RM2.78 (←→) **Share Price: RM2.64**

2Q14 Results - Another Outstanding Record

Results

- Outdid itself by registering another record breaking guarterly results of RM65.1m turnover and RM20.0m core PAT.
- 1H14 top line of RM87.9m was translated into higher-thanexpected a core net profit of RM24.0m, accounting for 68.4% of HLIB full year estimate.

Deviations

Revenue mix as highest-margin-MVS sales outpaced ABI and ECS.

Dividend Highlights

- None (2Q13: none).
- 2Q14 revenue more than doubled yoy as sales of all three product lines surged, with MVS, ABI and ECS grew by 142%, 118% and 102% yoy, respectively. Higher demand from customers is attributable to the improving business outlook in the semiconductor and electronics industries.
- Sequentially, turnover almost tripled as MVS, ABI and ECS sales grew by 263%, 137% and 50% qoq, respectively.
- In view of positive market outlooks in the semiconductor and electronics industries, ViTrox is optimistic on the growth prospect in FY14 with focus on market expansion activities, customer relationship building and product innovation.
- Analyst briefing will be hosted this morning which we expect to grasp better understanding of the company outlook.

Comments

- Referring to SEMI June preliminary data, semiconductor equipment industry's book-to-bill ratio was 1.09, sustaining above parity level since Sept 2013.
- 3-mohth average of worldwide bookings in June 2014 was USD1.47bn (+4.3% mom and +10.0% yoy).
- 3-mohth average of worldwide billings in June 2014 was USD1.34bn (-4.8% mom and +10.4% yoy).
- Global Industry Analysts projected the global market for surface mount technology (SMT) equipment to reach USD5.3bn by 2018, driven by recovery in electronics and semiconductor industries, new products and the need to upgrade older production lines. Furthermore, Asia-Pacific represents the largest market worldwide, while Latin America is projected to emerge as the fastest growing marking with a CAGR of 7.2% from 2010 to 2018.

Risks

 FOREX, downturn in semiconductor demand and equipment spending, patent infringement and technology imitation.

Forecasts

Unchanged pending analyst briefing.

BUY ←→, TP: RM2.78 ←→

Rating

- Positives undisputed 3D-AOI and AXI technology leader, great potential in winning more market share in the advent of global semiconductor recovery.
- Negatives MVS-S sales is dependent on single customer, majority of sales are non-recurring, highly competitive 2D-AOI market and prone to rapid advances in technology.

Valuation

 Reiterate BUY with unchanged TP of RM2.78, pegged to 1SD above 5-year historical average P/E multiple of 16.2x (see Figure #4) reflecting its solid exponential growth ahead.

Tan J Young

jytan@hlib.hongleong.com.my

(603) 2168 1082

KLCI	1874.8
Expected share price return	5.3%
Expected dividend return	1.1%
Expected total return	6.4%

Share price



Information

Bloomberg Ticker	VITRO MK
Bursa Code	0097
Issued Shares (m)	232.7
Market cap (RM m)	614.4
3-mth avg. volume ('000)	239.1
SC Shariah-Compliant	Yes

Price Performance	1M	3M	12M
Absolute	8.2	42.9	232.1
Relative	7.8	43.0	209.1

Major shareholders

Chu Jenn Weng	29.5%
Siaw Kok Tong	21.2%
Yeoh Shih Hoong	11.3%

Summary Earnings Table

		/		
FYE 31 Dec				
(RM'k)	2013A	2014E	2015E	2016E
Revenue	106,104	152,811	169,824	185,793
EBITDA	22,582	35,293	38,490	41,308
Pre-tax Profit	24,807	35,912	40,920	46,334
PATAMI	24,063	35,039	39,925	45,208
Adj PATAMI	24,063	35,039	39,925	45,208
Rep. EPS sen	10.35	15.07	17.17	19.44
Adj. EPS sen	10.35	15.07	17.17	19.44
Net DPS sen	2.25	3.01	3.43	3.89
Net DY (%)	0.85	1.14	1.30	1.47
P/E (x)	25.5	17.5	15.4	13.6
P/BV (x)	4.7	3.8	3.2	2.7
EV/EBITDA (x)	25.9	16.2	14.3	12.7
Net D/E %	NetCash I	NetCash I	NetCash I	NetCash
ROA %	14.4	17.5	17.0	16.5
ROE %	18.3	21.8	20.7	19.7
HLIB				

Page 1 of 5 22 August 2014

Figure #1 2Q14 Results Comparison

RMm	2Q13	1Q14	2Q14	YoY (%)	QoQ (%)	Comments
Revenue	28,356	22,828	65,103	129.6	185.2	YoY: Higher mainly due to increase in sales from all product lines, where MVS, ABI and ECS sales grew by 142%, 118% and 102% yoy, respectively. QoQ: Higher mainly due to increase in sales from all product lines, where MVS, ABI and ECS sales grew by 263%, 137% and 50% qoq, respectively.
EBITDA Marrin 9/	5,670 20.0%	4,236 18.6%	20,391 31.3%	259.6	381.4	Improved thanks to higher level of economy of scale and change in product mix as the highest-margin-MVS sales growth outpaced ABI and ECS.
EBITDA Margin %						margin improvements.
EBIT	4,967	3,439	19,325	289.1	461.9	Filtered down from EBITDA.
PBT	6,891	4,229	20,606	199.0	387.3	Filtered down from EBIT.
Reported PAT	6,483	3,987	19,996	208.4	401.5	Filtered down from PBT.
PATAMI	6,483	3,987	19,996	208.4	401.5	
Normalised PATAMI	6,483	3,987	19,996	208.4	401.5	
Reported EPS (sen)	2.79	1.71	8.60	208.4	401.5	Filtered down from PAT.
Adjusted EPS (sen)	2.79	1.71	8.60	208.4	401.5	

Company Data

Figure #2 1H14 Results Comparison

RMm	1H13	1H14	YoY (%)	Comments
Revenue	41,281	87,931	113.0	More than doubled due to robust sales from all product lines.
EBITDA	5,801	24,627	324.5	YoY: Improved thanks to higher level of economy of scale and change in product mix as the highest-margin-MVS sales growth outpaced ABI and ECS.
EBITDA Margin %	14.1%	28.0%		margin improvements.
EBIT	4,444	22,764	412.2	Filtered down from EBITDA.
PBT	7,610	24,835	226.3	Filtered down from EBIT.
Reported PAT	6,941	23,983	245.5	Filtered down from PBT.
PATAMI	6,941	23,983	245.5	
Normalised PATAMI	6,941	23,983	245.5	
Reported EPS (sen)	2.99	10.32	245.5	Filtered down from PAT.
Adjusted EPS (sen)	2.99	10.32	245.5	

Company Data


Figure #3 1H14 Results vs HLIB

RMm	Actual 1H14	HLIB FY14 Est.	Actual vs HLIB (%)	Comments
Revenue	87,931	152,811	57.5	Above expectations.
EBITDA	24,627	35,293	69.8	Above expectations.
EBITDA Margin %	28.0%	23.1%		
EBIT	22,764	32,178	70.7	
PBT	24,835	35,912	69.2	Above expectations.
Reported PAT	23,983	35,039	68.4	Above expectations.
PATAMI	23,983	35,039	68.4	
Normalised PATAMI	23,983	35,039	68.4	Above expectations.
Reported EPS (sen)	10.32	15.07	68.4	
Adjusted EPS (sen)	10.32	15.07	68.4	Above expectations.
D Dt. III.ID				

Company Data, HLIB

Page 2 of 5 22 August 2014

Figure #4 ViTrox's Historical 1-Year Forward P/E Band



Bloomberg, HLIB

Page 3 of 5 22 August 2014

ViTrox Corporation Berhad (BUY, PT: RM2.78, CP: RM2.64)

	_				=	= -			•		
Income statem	ent	Quarterly financial summary									
FYE 31 Dec (RM'k)	2012A	2013A	2014A	2015E	2016E	FYE 31 Dec (RM'k)	2Q13	3Q13	4Q13	1Q14	2Q14
Revenue	88,853	106,104	152,811	169,824	185,793	Revenue	28,356	36,305	28,518	22,828	65,103
COGS	(72,731)	(83,522)	(117,518)	(131,333)	(144,485)	COGS	(22,686)	(24,523)	(23,519)	(18,592)	(44,712)
EBITDA	16,122	22,582	35,293	38,490	41,308	EBITDA	5,670	11,782	4,999	4,236	20,391
D&A	(2,684)	(2,847)	(3,115)	(3,276)	(3,422)	D&A	(703)	(703)	(787)	(797)	(1,066)
EBIT	13,438	19,735	32,178	35,214	37,886	EBIT	4,967	11,079	4,212	3,439	19,325
Net Interest Income	8,101	5,072	3,734	5,706	8,448	Net Interest Income	1,924	728	1,178	790	1,281
Associates	0	0	0	0	0	Associates	0	0	0	0	0
Exceptionals	0	0	0	0	0	Exceptionals	0	0	0	0	0
PBT	21,539	24,807	35,912	40,920	46,334	PBT	6,891	11,807	5,390	4,229	20,606
Tax	(1,066)	(744)	(873)	(995)	(1,126)	Tax	(408)	56	(131)	(242)	(610)
PAT	20,473	24,063	35,039	39,925	45,208	PAT	6,483	11,863	5,259	3,987	19,996
Minority Interests	0	0	0	0	0	Minority Interests	0	0	0	0	0
PATAMI	20,473	24,063	35,039	39,925	45,208	PATAMI	6,483	11,863	5,259	3,987	19,996
Adj. PATAMI	20,473	24,063	35,039	39,925	45,208	Adj. PATAMI	6,483	11,863	5,259	3,987	19,996
Basic Shares (m)	232.50	232.50	232.50	232.50	232.50	Basic Shares (m)	232.5	232.5	232.5	232.5	232.5
Rep. EPS sen	8.81	10.35	15.07	17.17	19.44	Rep. EPS sen	2.79	5.10	2.26	1.71	8.60
Adj. EPS sen	8.81	10.35	15.07	17.17	19.44	Adj. EPS sen	2.79	5.10	2.26	1.71	8.60
Adj. FD EPS sen	8.81	10.35	15.07	17.17	19.44	Adj. FD EPS sen	2.79	5.10	2.26	1.71	8.60

Balance sheet					
FYE 31 Dec (RM'k)	2012A	2013A	2014A	2015E	2016E
Cash	43,915	40,458	52,745	75,244	101,189
Receivables	39,203	51,787	62,507	68,306	74,783
Inventories	27,972	36,978	44,936	49,377	54,358
Investments	0	0	0	0	0
Fixed Assets	30,060	31,939	33,748	35,396	36,897
Intangibles	2,602	3,966	3,966	3,966	3,966
Other Assets	1,816	2,256	2,256	2,256	2,256
Ttl Assets	145,568	167,384	200,158	234,544	273,449
Payables	16,793	17,281	20,836	22,769	24,928
Short Term Debt	1,249	1,338	1,338	1,338	1,338
Long Term Debt	1,249	1,338	1,338	1,338	1,338
Other Liabilities	11,842	16,207	16,207	16,207	16,207
Ttl Liab	31,133	36,164	39,719	41,652	43,811
S/H Funds	114,435	131,220	160,439	192,893	229,638
Minority Interests	0	0	0	0	0
Total S/H Equity	114,435	131,220	160,439	192,893	229,638
Ttl Liab&S/H Fds	145,568	167,384	200,158	234,544	273,449

Cashflow Analysis									
FYE 31 Dec (RM'k)	2012A	2013A	2014A	2015E	2016E				
EBITDA	16,122	22,582	35,293	38,490	41,308				
Net Interest	8,101	5,072	3,734	5,706	8,448				
Tax Paid	(1,066)	(744)	(873)	(995)	(1,126)				
Working Cap Chgs	(16,717)	(21,102)	(15,123)	(8,307)	(9,299)				
Other	(3,364)	1,544	0	0	0				
Operating CF	3,076	7,352	23,031	34,894	39,331				
FĊF	(824)	3,567	18,107	29,970	34,407				
CAPEX	(3,900)	(3,785)	(4,924)	(4,924)	(4,924)				
Asset Sales	2,803	0	0	0	0				
Acquisitions	0	0	0	0	0				
Other	1,148	(476)	0	0	0				
Investing CF	51	(4,261)	(4,924)	(4,924)	(4,924)				
Dividends	(4,639)	(5,203)	(5,820)	(7,472)	(8,462)				
Debt Chgs	3,970	(397)	0	0	0				
Other	(667)	(956)	0	0	0				
Financing CF	(1,336)	(6,556)	(5,820)	(7,472)	(8,462)				
Net Cashflow	1,791	(3,465)	12,287	22,499	25,945				
·									

Valuation Ratios									
FYE 31 Dec (RM'k)	2012A	2013A	2014A	2015E	2016E				
PER (x)	29.98	25.51	17.52	15.37	13.58				
Adj. PER (x)	29.98	25.51	17.52	15.37	13.58				
FD PER (x)	29.98	25.51	17.52	15.37	13.58				
Net DPS sen	1.00	2.25	3.01	3.43	3.89				
Net DY (%)	0.38	0.85	1.14	1.30	1.47				
Book/share sen	49.22	56.44	69.01	82.96	98.77				
P/Book (x)	5.36	4.68	3.83	3.18	2.67				
FCF/share sen	(0.35)	1.53	7.79	12.89	14.80				
FCF yield (%)	(0.13)	0.58	2.95	4.88	5.61				
Mkt Cap	613,800	613,800	613,800	613,800	613,800				
Net Cash(Debt)	41,417	37,782	50,069	72,568	98,513				
EV	572,383	576,018	563,731	541,232	515,287				
EV/EBITDA (x)	35.5	25.5	16.0	14.1	12.5				
ROE (%)	17.89	18.34	21.84	20.70	19.69				
Current Ratio (x)	6.11	5.97	6.35	7.10	7.84				
Quick Ratio (x)	4.58	4.28	4.59	5.29	6.00				
Interest Cover (x)	NoDebt	NoDebt	43.99	48.14	51.79				

KUE (%)	17.09	10.34	Z1.04	20.70	19.09
Current Ratio (x)	6.11	5.97	6.35	7.10	7.84
Quick Ratio (x)	4.58	4.28	4.59	5.29	6.00
nterest Cover (x)	NoDebt	NoDebt	43.99	48.14	51.79
Other Ratios					
FYE 31 Dec (RM'k)	2012A	2013A	2014A	2015E	2016E
Sales Growth (%)	12.2	19.4	44.0	11.1	9.4
EBITDA Growth (%)	(16.5)	40.1	56.3	9.1	7.3
EBIT Growth (%)	(22.7)	46.9	63.0	9.4	7.6
PBT Growth (%)	(6.4)	15.2	44.8	13.9	13.2
PAT Growth (%)	(7.9)	17.5	45.6	13.9	13.2
EBITDA Margin (%)	18.1	21.3	23.1	22.7	22.2
EBIT Margin (%)	15.1	18.6	21.1	20.7	20.4
PBT Margin (%)	24.2	23.4	23.5	24.1	24.9
Net Profit Margin (%)	23.0	22.7	22.9	23.5	24.3
Net Debt/Equity (%)	NetCash	NetCash	NetCash	NetCash	NetCash
CAPEX/Sales (%)	24.2	16.8	14.0	12.8	11.9

Page 4 of 5 22 August 2014

Disclaimer

The information contained in this report is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, are made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the report.

Accordingly, neither Hong Leong Investment Bank Berhad nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication.

Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. Hong Leong Investment Bank Berhad has no obligation to update its opinion or the information in this report.

Investors are advised to make their own independent evaluation of the info contained in this report and seek independent financial, legal or other advice regarding the appropriateness of investing in any securites or the investment strategies discussed or recommended in this report. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represent a personal recommendation to you.

Under no circumstances should this report be considered as an offer to sell or a solicitation of any offer to buy any securities referred to herein.

Hong Leong Investment Bank Berhad and its related companies, their associates, directors, connected parties and/or employeees may, from time to time, own, have positions or be materially interested in any securities mentioned herein or any securites related thereto, and may further act as market maker or have assumed underwriting commitment or deal with such securities and provide advisory, investment or other services for or do business with any companies or entities mentioned in this report. In reviewing the report, investors should be aware that any or all of the foregoing among other things, may give rise to real or potential conflict of interests.

This research report is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this report, unless specifically indicated otherwise, is under copyright to Hong Leong Investment Bank Berhad. This research report and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.

This report may provide the addresses of, or contain hyperlinks to, websites. Hong Leong Investment Bank Berhad takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to Hong Leong Investment Bank Berhad own website material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or Hong Leong Investment Bank Berhad website shall be at your own risk.

- 1. As of 22 August 2014, Hong Leong Investment Bank Berhad has proprietary interest in the following securities covered in this report:
 (a) -.
- 2. As of 22 August 2014, the analyst, Tan J Young who prepared this report, has interest in the following securities covered in this report: (a) -.

Published & Printed by Hong Leong Investment Bank Berhad (10209-W)

Level 23, Menara HLA No. 3, Jalan Kia Peng 50450 Kuala Lumpur Tel 603 2168 1168 / 603 2710 1168 Fax 603 2161 3880

Equity rating definitions

Positive recommendation of stock under coverage. Expected absolute return of more than +10% over 12-months, with low risk of sustained downside.

Positive recommendation of stock under coverage. Expected absolute return of more than +10% over 6-months. Situational or arbitrage trading opportunity.

Neutral recommendation of stock under coverage. Expected absolute return between -10% and +10% over 12-months, with low risk of sustained downside.

Negative recommendation of stock under coverage. Expected absolute return of less than -10% over 6-months. Situational or arbitrage trading opportunity.

Negative recommendation of stock under coverage. High risk of negative absolute return of more than -10% over 12-months.

No research coverage, and report is intended purely for informational purposes.

Industry rating definitions

OVERWEIGHT	The sector, based on weighted market capitalization, is expected to have absolute return of more than +5% over 12-months.
NEUTRAL	The sector, based on weighted market capitalization, is expected to have absolute return between -5% and +5% over 12-months.
UNDERWEIGHT	The sector, based on weighted market capitalization, is expected to have absolute return of less than -5% over 12-months.

Page 5 of 5 22 August 2014